Why Delivery Method Matters in Ketamine Therapy
In mental health care, how a medication is delivered matters almost as much as what it is. For people exploring ketamine-based treatments, one common question is:
Why is Spravato a nasal spray, rather than a pill, IV, or injection?
Spravato (a brand name of esketamine) is the only FDA-approved ketamine-based medication for treatment-resistant depression, and its intranasal form is no accident.[1,2] The choice reflects careful balancing of absorption, how strongly it binds to its target receptors, and insurance coverage — all key to making this treatment both effective and accessible.
In this article, Lumin Health explores the science behind Spravato’s nasal formulation and why it is growing as a reliable option in clinical practice of mental health treatment.
Mucous Membranes and Ready Absorption of Spravato
The inside of your nose is lined with mucous membranes — specialized tissue rich with blood vessels and ideal for rapid drug absorption. This makes the intranasal route a powerful way to deliver medications that need to:
- Act quickly
- Bypass liver metabolism (known as “first-pass” metabolism) long enough to be effective
With Spravato, the active ingredient is S-ketamine — one of the two mirror-images of ketamine — that is absorbed efficiently through these membranes, entering the bloodstream and reaching the brain in minutes.[3,4]
“The nasal route is predictable. We know how much is being absorbed, and it avoids a lot of the variability we see with other non-injected forms.” — Dr. Ben Yudkoff
This route allows for relatively fast onset, without the invasiveness of IV infusions — especially helpful in outpatient psychiatric settings.
Lower Drug Volume = Less Leakage, Higher Fidelity
One challenge with intranasal medications is loss of drug — through leakage or swallowing. Spravato addresses this by using a low-volume, high-concentration spray, which reduces:
- Drip-back into the throat with unintentional swallowing (which can decrease effectiveness)
- Dripping out of the nose
- Dosing inconsistencies
“It’s not just that it’s nasal — it’s that it’s engineered for nasal use.” — Dr. Ben Yudkoff
This attention to volume and delivery fidelity means clinicians can feel more confident about what dose is actually being absorbed — crucial in a treatment where both effectiveness and side effects are dose-sensitive.
How This Ties to Spravato FDA Approval and Insurance Coverage
Spravato’s pharmacology and nasal format are central to its regulatory and insurance status.
The nasal form of esketamine, Spravato, was patented by Janssen and received FDA approval for treatment-resistant depression due to its demonstrated safety and efficacy.[1,5] Because of this, Spravato meets criteria for coverage by many insurers.
In contrast, IV ketamine and other formats are typically not covered as they are used “off-label” — meaning mental health treatment is not in the approved use cases for ‘generic’ ketamine, which is typically only in anesthetic contexts. This is the case even though IV ketamine infusions or intramuscular ketamine injections may be appropriate in some cases.
“We’ve had patients choose Spravato because it’s covered, reliable, and supervised in a way that makes them feel safe.” — Dr. Ben Yudkoff
This makes the nasal spray format a practical bridge between effective neuroscience and real-world accessibility.
Spravato (esketamine) as a Nasal Spray
Spravato’s nasal spray formulation isn’t meant to be a convenience — it’s a carefully chosen strategy. It leverages the body’s natural absorption pathways to deliver fast, robust relief in a format that fits both clinical safety protocols and insurance frameworks.
Whether nasal, IV, or otherwise, the route of ketamine administration should match the patient’s needs, diagnosis, and life context. At Lumin Health, we help patients understand these options so they can make informed decisions grounded in clarity, not hype.
References
- Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019;176(6):428-438. PubMed
- Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616-630. PubMed
- Peltoniemi MA, Hagelberg NM, Olkkola KT, et al. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clin Pharmacokinet. 2016;55(9):1059-77. PubMed
- Jelen LA, Young AH, Stone JM. Ketamine: A tale of two enantiomers. J Psychopharmacol. 2021;35(2):109-123. PubMed
- Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247-52. PubMed
Take the first step today.
If you or a loved one in Massachusetts and the greater Washington DC/Maryland area is struggling with depression or anxiety, Lumin Health's team of experts is ready to help. Book a free 20-minute consultation to learn if ketamine therapy could be the breakthrough you've been looking for.
Available in Massachusetts and the greater Washington DC/Maryland area.
Frequently Asked Questions
Why is esketamine (Spravato) given as a nasal spray instead of a pill or injection?
The inside of your nose is lined with tissue that's rich in blood vessels, so medication delivered there is absorbed quickly and bypasses processing by the liver. That absorption path, combined with predictable dosing and insurance coverage, is why the nasal route was chosen for esketamine (Spravato).
How quickly does esketamine (Spravato) nasal spray start working?
Esketamine (Spravato) is absorbed through the mucous membranes in your nose and reaches your bloodstream and brain within minutes. That fast absorption is one reason the nasal route was chosen, and it supports the observation period that follows the dose.
Is esketamine (Spravato) nasal spray better than IV ketamine?
Not necessarily; each has different tradeoffs. IV ketamine allows precise dosing and rapid onset but requires more clinical infrastructure and is generally used off-label, so it's usually an out-of-pocket cost. Esketamine (Spravato)'s nasal route was chosen for reliable absorption combined with ease of use and typical insurance coverage.
How does esketamine (Spravato)'s low-volume spray design affect dosing?
Each device delivers a small, fixed amount of concentrated solution across two sprays, which limits drip back and keeps the dose you actually absorb consistent. That consistency matters, since both how well the medication works and its side effects are sensitive to dose.
Is esketamine (Spravato) nasal spray covered by insurance?
Esketamine (Spravato) is FDA-approved for treatment-resistant depression and is often covered by insurance when prescribed by a REMS-certified provider at a certified practice. Off-label options like IV ketamine or compounded nasal sprays are typically not FDA-approved for depression and aren't always reimbursed.
